Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Metagenomi, Inc.. The associated price target remains the same with $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mitchell Kapoor’s rating is based on Metagenomi, Inc.’s promising developments and strategic partnerships. The company is on track to file for Investigational New Drug (IND) and Clinical Trial Application (CTA) for its gene editing candidate, MGX-001, targeting Hemophilia A by 2026. This candidate has shown durable results in non-human primate studies, indicating potential for successful human applications.
Additionally, Metagenomi’s collaboration with Ionis Pharmaceuticals is expected to yield at least one development candidate in 2025, focusing on gene knockdown therapeutics for various cardiometabolic conditions. Financially, the company maintains a strong cash position, providing an operational runway into 2027, and the stock is trading below cash value, suggesting significant upside potential. Kapoor’s valuation analysis supports a price target of $7 per share, underpinned by a 25% probability of approval for key programs, despite acknowledging inherent risks such as clinical delays and data outcomes.
Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ionis Pharmaceuticals, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of -9.8% and a 42.49% success rate on recommended stocks.